Olema Pharmaceuticals, Inc. announced the appointment of Naseem Zojwalla, M.D., as Chief Medical Officer. Dr. Zojwalla previously led clinical development and strategy at biopharmaceutical companies, including Turning Point Therapeutics and Peloton Therapeutics and served in lead clinical roles at multiple oncology-focused companies, including Onyx Pharmaceuticals, ImClone Systems, and Eisai Inc. She brings with her extensive experience in building out world-class clinical development, operations, and pharmacovigilance teams to support expanding programs, advancing clinical assets from Phase 1 through registrational studies, and regulatory experience with U.S. and European authorities. Dr. Zojwalla succeeds Pamela Klein, M.D., who as part of a planned leadership transition, will continue to work with the company both as a senior strategic advisor and as a newly appointed member of Olema's Scientific Advisory Board.

Dr. Klein has served as Chief Medical Officer for Olema in a consultant capacity since early 2020, and previously served as a drug development consultant to the company for more than a decade.